

# WHO DRUG INFORMATION

Volume 35 • Number 2 • 2021

**Proposed INN: List 125**

International Nonproprietary Names for Pharmaceutical Substances



**World Health  
Organization**

## WHO Drug Information

WHO Drug Information provides an overview of topics relating to medicines development, regulation, quality and safety. The journal also publishes and reports on guidance documents and includes lists of International Nonproprietary Names for Pharmaceutical Substances (INN), ATC/DDD classification and monographs for The International Pharmacopoeia. It presents and describes WHO policies and activities while reflecting on technical and pharmaceutical topics of international and regional interest.

WHO Drug Information is published four times a year and can be ordered from:

WHO Press, World Health Organization, 1211 Geneva 27, Switzerland.

e-mail: [bookorders@who.int](mailto:bookorders@who.int) or on line at <http://www.who.int/bookorders>

WHO Drug Information can be viewed at:

<https://www.who.int/our-work/access-to-medicines-and-health-products/who-drug-information>

---

### WHO Drug Information, Vol. 35, No. 2, 2021

ISBN 978-92-4-003205-7 (electronic version)

ISBN 978-92-4-003206-4 (print version)

ISSN 1010-9609

#### © World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO Drug Information, Vol. 35, No. 2, 2021. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# WHO Drug Information

## Contents

### Consultation Documents

- 270 Linezolid (*linezolidum*)
- 278 Remdesivir (*remdesivirum*)
- 287 Remdesivir intravenous infusion (*remdesiviri infusio intraveno*)
- 294 Ulipristal acetate (*ulipristali acetas*)
- 301 Ulipristal acetate tablets (*ulipristali acetas compressi*)
- 306 WHO Guidelines on the Transfer of Technology Pharmaceutical Manufacturing
- 334 WHO/UNFPA Guidance on Natural Rubber Latex Condom Stability Studies

### ATC/DDD Classification

- 352 ATC/DDD Classification (Temporary)
- 356 ATC/DDD Classification (Final)

### International Nonproprietary Names (INN)

- 361 Proposed INN List No. 125



#### Extraordinary (virtual) International Conference of Drug Regulatory Authorities (ICDRA) 20 to 24 September 2021

World Health Organization is pleased to announce the organization of an extraordinary International Conference of Drug Regulatory Authorities (ICDRA) in September 2021. This virtual conference will give the opportunity to the global regulatory community and other key stakeholders to exchange information, best practices and collaborative approaches related to regulation of medical products, especially important during the current challenging times of the COVID-19 pandemic. The decision for the extraordinary ICDRA was taken as the planned 2020 ICDRA which should have taken place in India had to be cancelled due to COVID-19 pandemic. The conference is intended to bridge to the 19th ICDRA, which will be organised in India in 2022, when situation permits.

The theme of the extraordinary Conference planned for September is “Smart Regulation: Timely Delivery of Quality Assured Medical Products for All during the Global Pandemic”. The Conference will be held virtually with daily sessions of two hours from 13:00 to 15:00 (CET) from Monday 20 to Friday 24 September 2021. Information regarding the registration process and the programme will be released in the coming weeks. WHO is looking forward to welcoming all to this extraordinary ICDRA 2021 Conference.

**Link to WHO ICDRA site:**

<https://www.who.int/teams/regulation-prequalification/regulation-and-safety/regulatory-convergence-networks/icdra>

**Note:** The online version of this issue is available at:

<https://www.who.int/our-work/access-to-medicines-and-health-products/who-drug-information>

# LINEZOLID

## (*LINEZOLIDUM*)

### ***DRAFT FOR COMMENTS***

Please send any comments you may have on this draft working document to **Dr Herbert Schmidt**, Technical Officer, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications (email: [schmidth@who.int](mailto:schmidth@who.int)), with a copy to Ms Sinéad Jones (email: [jonessi@who.int](mailto:jonessi@who.int)) by **31 July 2021**.

Our working documents are sent out electronically and they will be placed on the WHO Medicines website (<https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/pharmaceuticals/current-projects>) for comments under the “*Working documents in public consultation*” link.

If you wish to receive our draft guidelines, please send your e-mail address to [jonessi@who.int](mailto:jonessi@who.int) and your name will be added to our electronic mailing list.

*[Note from the Secretariat. The draft proposal is based on information submitted by manufacturers and found in other pharmacopoeias and in the scientific literature.*


*All stakeholders, in particular manufacturers of this product, regulatory authorities, quality control laboratories and procurement agencies, are invited to provide their feedback to the Secretariat of The International Pharmacopoeia. Your support will help ensure that the proposed monograph adequately controls the quality of Linezolid active pharmaceutical ingredient on the market.*

*Comments are in particular sought on the values used for the correction factors for impurities I and J.]*

# LINEZOLID

(*LINEZOLIDUM*)

## Graphic formula



**Molecular formula.** C<sub>16</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>

**Relative molecular mass.** 337.4

**Chemical name.** *N*-[[[(*S*)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl] methyl] acetamide; CAS Reg. No. 165800-03-3.

**Description.** A white to off-white powder.

**Solubility.** Sparingly soluble in methanol R; soluble in dichloromethane R.

**Category.** Antituberculosis.

**Storage.** Linezolid should be kept in a tight container, protected from light and moisture.

**Additional information.** Linezolid may exhibit polymorphism.

## Requirements

**Manufacture.** The production method is validated to demonstrate that genotoxic impurities are adequately controlled in the final product.

**Definition.** Linezolid contains not less than 99.0% and not more than 101.0% (“Assay”, Method A) and not less than 98.0% and not more than 102.0% (“Assay”, Method B) of C<sub>16</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>, calculated with reference to the anhydrous substance.

**Identity tests**

- Either test A or test B or tests C and D may be applied.
  - A. Carry out the examination as described under *1.7 Spectrophotometry in the infrared region*. The infrared absorption spectrum is concordant with the spectrum obtained from linezolid RS.

If the spectra thus obtained are not concordant, repeat the test using the residues obtained by separately dissolving the test substance and linezolid RS in a small amount of ethanol R and evaporating to dryness. The infrared absorption spectrum of the test substance is concordant with the spectrum obtained from linezolid RS.
  - B. Carry out the test as described under *1.14.4 High-performance liquid chromatography* using the conditions given under “Assay”. Record the UV spectrum of the principle peak in the chromatograms with a diode array detector in the range of 200 nm to 400 nm. The retention time and the UV spectrum of the principal peak in the chromatogram obtained with solution (1) correspond to the retention time and UV spectrum of the peak due to linezolid in the chromatogram obtained with solution (2).
  - C. Carry out the test as described under *1.14.1 Thin-layer chromatography* using silica gel R6 as the coating substance and a freshly prepared mixture of acetone R, toluene R and glacial acetic acid R (45:45:10 V/V/V) as the mobile phase. Apply separately to the plate 2 µL of each of the following 2 solutions in methanol R containing (A) 5 mg of the test substance per mL and (b) 5 mg of linezolid RS per mL. After removing the plate from the chromatographic chamber, allow it to dry in air or in a current of air. Examine the plate under ultraviolet light (254 nm). Spray the plate with potassium permanganate, basic (~5 g/L) TS and examine the plate in daylight. The principal spot in the chromatogram obtained with solution (A) corresponds in position, appearance and intensity with the spot due to linezolid in the chromatogram obtained with solution (B).
  - D. Dissolve 20 mg of the test substance in methanol R and dilute to 100 mL with the same solvent. Dilute 1 mL of this solution to 20 mL. Record an absorption spectrum of the solution in the range from 200 nm to 400 nm as described under *1.6 Spectrophotometry in the visible and ultraviolet regions*. The spectrum exhibits a maximum at 258 nm.

**Water.** Determine as described under *2.8 Determination of water by the Karl Fischer method*, Method A. Use 0.300 g of the test substance. The water content is not more than 5 mg/g.

**Sulfated ash (2.3).** Not more than 2.0 mg/g

**Heavy metals.** Use 2.0 g of the test substance for the preparation of the test solution as described under *2.2.3 Limit test for heavy metals*, Procedure 3. Determine the heavy metals content according to Method A; not more than 10 µg/g.

**Impurity E (Linezolid R-isomer).** Carry out the test as described under 1.14.4 *High-performance liquid chromatography* using a stainless-steel column (15 cm x 4.6 mm) packed with silica particles, the surface of which has been modified with chemically-bonded amylose tris-3,5-dimethylphenylcarbamate, (5  $\mu\text{m}$ )<sup>1</sup>.

As mobile phase, use a mixture of 960 volumes acetonitrile R, 40 volumes of dehydrated ethanol R, 1 volume of n-butylamine R and 1.6 volumes of trifluoroacetic acid R. Operate at a flow rate of 0.8 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm. Maintain the column temperature at 40 °C. Use a mixture of 960 volumes of acetonitrile R and 40 volumes of dehydrated ethanol R as diluent. For solution (1), dissolve 25.0 mg of the test substance and dilute to 50.0 mL. For solution (2) dilute 1.0 mL of solution (1) to 100.0 mL. Dilute 1.0 mL of this solution to 10.0 mL. For solution (3), dissolve 5.0 mg each of linezolid RS and linezolid impurity E RS and dilute to 200.0 mL.

Inject 5  $\mu\text{L}$  each of solutions (1), (2) and (3). Record the chromatograms for about two times the retention time of linezolid.

In the chromatogram obtained with solution (3), impurity E is eluted with a relative retention of about 0.39 with reference to linezolid. The test is not valid unless in the chromatogram obtained with solution (3) the resolution between the peak of impurity E and the peak of linezolid is greater than 10. The test is also not valid unless in the chromatogram obtained with solution (2) the peak due to linezolid is detected with a signal-to-noise ratio of at least 10.

In the chromatogram obtained with solution (1):

- the area of any peak corresponding to impurity E is not greater than 3 times the area of the peak due to linezolid in the chromatogram obtained with solution (2) (0.3%).

**Related substances.** Carry out the test as described under 1.14.4 *High-performance liquid chromatography* using a stainless-steel column (25 cm x 4.6 mm), packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5  $\mu\text{m}$ )<sup>2</sup>.

---

<sup>1</sup> Phenomenex Lux Amylose-1 or Chiralpak IA column was found suitable.

<sup>2</sup> An Inertsil ODS-3V column was found suitable.

Use the following conditions for gradient elution:

- mobile phase A: potassium dihydrogen phosphate (6.8 g/L) TS.
- mobile phase B: methanol R.

Time (minutes)	Mobile phase A (% v/v)	Mobile phase B (% v/v)	Comments
0–5	65	35	Isocratic
5–25	65 to 35	35 to 65	Linear gradient
25–30	35	65	Isocratic
30–31	35 to 65	65 to 35	Return to initial composition
31–40	65	35	Re-equilibration

Operate with a flow rate of 1.0 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 251 nm. Maintain the column temperature at 50 °C. Prepare the following solutions in a mixture of 30 volumes of methanol R and 70 volumes of water R. For solution (1), dissolve 40.0 mg of the test substance in 50.0 mL. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL. For solution (3) dilute 1.0 mL of solution (2) to 10.0 mL. For solution (4) dissolve 5.0 mg each of linezolid RS and linezolid impurity D RS in 100.0 mL.

Inject 10 µL each of solutions (1), (2), (3) and (4).

Use the chromatogram obtained with solution (4) to identify the peaks due to linezolid and impurity D in the chromatogram obtained with solution (1). The impurity peaks, if present, are eluted at the following relative retention times with reference to linezolid (retention time about 13.6 minutes): impurity G about 0.28; impurity C about 0.38; impurity F about 0.69; impurity H about 0.73; impurity D about 1.08; impurity J about 1.46; impurity B about 1.57; impurity A about 1.62; impurity I about 1.95.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23687](https://www.yunbaogao.cn/report/index/report?reportId=5_23687)

